---
title: "Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/300347.SZ.md"
symbol: "300347.SZ"
name: "Hangzhou Tigermed Consulting Co., Ltd."
industry: "Life Sciences Tools and Services"
---

# Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Location | CN Market |
| Website | [www.tigermedgrp.com](https://www.tigermedgrp.com) |

## Company Profile

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers precl...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.50)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 12 / 27 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -3.53% |  |
| Net Profit YoY | -36.15% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.48 |  |
| Dividend Ratio | 0.49% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 52.42B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 6.56B |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2.90% | C |
| Profit Margin | 9.33% | B |
| Gross Margin | 27.47% | C |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -3.53% | D |
| Net Profit YoY | -36.15% | D |
| Total Assets YoY | -4.93% | D |
| Net Assets YoY | 1.18% | C |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1071.86% | B |
| OCF YoY | -3.53% | D |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.22 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 14.16% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Hangzhou Tigermed Consulting Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "2.90%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "9.33%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "27.47%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-3.53%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-36.15%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-4.93%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.18%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1071.86%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-3.53%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.22",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "14.16%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | WuXi AppTec (SH.603259) | A | A | C | B | B | B |
| 02 | Pharmaron (SZ.300759) | B | B | C | C | B | B |
| 03 | Chemexpress (SH.688131) | B | A | C | C | B | B |
| 04 | HitGen (SH.688222) | B | B | D | B | B | B |
| 05 | Sepax Technologies (SH.688758) | C | B | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 85.63 | 13/27 | 163.92 | 112.83 | 77.15 |
| PB | 2.48 | 7/27 | 2.54 | 2.33 | 2.05 |
| PS (TTM) | 7.99 | 12/27 | 7.99 | 7.32 | 6.56 |
| Dividend Yield | 0.49% | 8/27 | 1.23% | 0.56% | 0.49% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-11T16:00:00.000Z

Total Analysts: **16**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 9 | 56% |
| Overweight | 4 | 25% |
| Hold | 1 | 6% |
| Underweight | 2 | 13% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 60.88 |
| Highest Target | 82.50 |
| Lowest Target | 40.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/300347.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/300347.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/300347.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.